Xiamen Amoytop Biotech Past Earnings Performance
Past criteria checks 5/6
Xiamen Amoytop Biotech has been growing earnings at an average annual rate of 46.4%, while the Biotechs industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 30.3% per year. Xiamen Amoytop Biotech's return on equity is 29.9%, and it has net margins of 27%.
Key information
46.4%
Earnings growth rate
45.7%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 30.3% |
| Return on equity | 29.9% |
| Net Margin | 27.0% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Xiamen Amoytop Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2,226 | 600 | 1,126 | 234 |
| 31 Dec 23 | 2,100 | 555 | 1,058 | 229 |
| 30 Sep 23 | 1,843 | 456 | 951 | 190 |
| 30 Jun 23 | 1,716 | 356 | 921 | 174 |
| 31 Mar 23 | 1,601 | 314 | 867 | 166 |
| 31 Dec 22 | 1,527 | 287 | 840 | 149 |
| 30 Sep 22 | 1,466 | 254 | 852 | 124 |
| 30 Jun 22 | 1,378 | 243 | 832 | 93 |
| 31 Mar 22 | 1,262 | 204 | 772 | 83 |
| 31 Dec 21 | 1,132 | 181 | 698 | 80 |
| 30 Sep 21 | 1,043 | 168 | 629 | 86 |
| 30 Jun 21 | 904 | 142 | 552 | 79 |
| 31 Mar 21 | 822 | 128 | 506 | 76 |
| 31 Dec 20 | 794 | 117 | 503 | 74 |
| 30 Sep 20 | 762 | 98 | 495 | 57 |
| 30 Jun 20 | 771 | 95 | 495 | 57 |
| 31 Mar 20 | 771 | 86 | 505 | 52 |
| 31 Dec 19 | 730 | 64 | 485 | 50 |
| 30 Sep 19 | 665 | 58 | 441 | 50 |
| 31 Dec 18 | 448 | 16 | 319 | 38 |
| 31 Dec 17 | 323 | 5 | 255 | 18 |
| 31 Dec 16 | 280 | 29 | 203 | 9 |
Quality Earnings: 688278 has a high level of non-cash earnings.
Growing Profit Margin: 688278's current net profit margins (27%) are higher than last year (19.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688278's earnings have grown significantly by 46.4% per year over the past 5 years.
Accelerating Growth: 688278's earnings growth over the past year (91.3%) exceeds its 5-year average (46.4% per year).
Earnings vs Industry: 688278 earnings growth over the past year (91.3%) exceeded the Biotechs industry -3.9%.
Return on Equity
High ROE: 688278's Return on Equity (29.9%) is considered high.